Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic octapeptide analog of somatostatin with a much longer half-life than the natural hormone. FDA-approved for acromegaly, carcinoid tumors, and VIPomas. One of the foundational peptide drugs in endocrinology.
A synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved for HIV-associated lipodystrophy. One of the few peptides with a clear FDA-approved indication, making it a useful reference point for the broader GHRH analog class.
Binds to somatostatin receptors (primarily SSTR2 and SSTR5), inhibiting growth hormone, glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits GI motility and secretion.
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile GH release. Reduces visceral adipose tissue (VAT) through GH-mediated lipolysis. Maintains the natural pulsatile pattern of GH secretion, preserving feedback mechanisms.
- Acromegaly
- Carcinoid syndrome
- VIPomas
- GI bleeding (variceal)
- Dumping syndrome
- HIV-associated lipodystrophy (FDA-approved)
- Visceral fat reduction
- Metabolic health improvement
- Growth hormone optimization (off-label)
- Cognitive function (emerging research in older adults)
- Gallstones (common with long-term use)
- GI side effects (diarrhea, nausea)
- Hyperglycemia or hypoglycemia
- Injection site pain
- Bradycardia
- Injection site reactions (common)
- Fluid retention and edema
- Arthralgia (joint pain)
- Potential glucose metabolism effects
- Contraindicated in active malignancy
FDA-approved as Sandostatin (1988, subcutaneous) and Sandostatin LAR (1998, monthly depot). Generic octreotide available. Widely used in endocrinology and oncology.
FDA-approved as Egrifta (tesamorelin for injection) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also available through compounding pharmacies for off-label use with a physician prescription.
- Octreotide in the treatment of acromegaly
1990 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.